FirstImpact: FDA Approval of Aubagio
Following US approval of Aubagio (teriflunomide; Sanofi/Genzyme) for use in Relapsing Remitting Multiple Sclerosis patients (RRMS), FirstWord interviewed nearly 300 US-based neurologists within 24 hours of the announcement. Based on this poll, this FirstImpact report identifies prescribing intentions and attitudes of practicing physicians to measure the impact of Aubagio’s approval.
The report presents the key insights gained from this major poll of neurologists. The research and analysis identifies the main clinical and commercial factors expected to influence the drug’s positioning against current and upcoming rivals in the MS treatment algorithm and examines Aubagio’s future prescribing trends.
The report also draws upon recent news coverage, analysis, and other market research undertaken by FirstWord, to provide background information about Aubagio, its development and its potential commercial positioning. The addition of key analyst opinion and consensus product forecasts for oral MS therapies provide a commercial perspective set against the views expressed by physicians.
The report and related data pack provides a comprehensive analysis of physicians’ reactions for industry professionals who need to immediately understand the impact of breaking news.
Key Benefits
This report will be of value to pharma directors and managers with responsibilities in the following areas:
FirstImpact’s Aubagio FDA Approval Report is delivered in two complimentary formats:
FirstImpact survey findings show 82 percent of neurologists are generally aware of Aubagio and the majority of these respondents intend to prescribe the drug in the future.
Interviewed physicians did not consider Aubagio’s price to be a major factor influencing its prescribing, compared with its clinical factors.
Interviewed neurologists position the Aubagio as second to Gilenya, while industry analysts see the therapy generating less revenue than BG-12 and Gilenya.
According to poll results, 22 percent of respondents anticipated they will use Aubagio as a monotherapy 90 to 100 percent of the time.
The report presents the key insights gained from this major poll of neurologists. The research and analysis identifies the main clinical and commercial factors expected to influence the drug’s positioning against current and upcoming rivals in the MS treatment algorithm and examines Aubagio’s future prescribing trends.
The report also draws upon recent news coverage, analysis, and other market research undertaken by FirstWord, to provide background information about Aubagio, its development and its potential commercial positioning. The addition of key analyst opinion and consensus product forecasts for oral MS therapies provide a commercial perspective set against the views expressed by physicians.
The report and related data pack provides a comprehensive analysis of physicians’ reactions for industry professionals who need to immediately understand the impact of breaking news.
Key Benefits
- Obtain insights into neurologists’ positioning of Aubagio
- Review the expected impact of Aubagio on physician prescribing
- Understand neurologist perceptions of Aubagio versus other launched and pipeline oral therapies through poll results
- Identify the most influential factors for Aubagio prescribing
- Compare the efficacy and safety of Aubagio versus rival MS drugs
- Identify the opportunities and challenges facing Aubagio
- Review MS analysts’ commercial expectations for Aubagio
- Plan and align your investments in the future MS product market
This report will be of value to pharma directors and managers with responsibilities in the following areas:
- Business Development
- New Product Planning
- Market Research
- Strategic brand planning
- Forecasting and marketing professionals
- Medical Affairs
- Clinical Trials
- Relationship Management
FirstImpact’s Aubagio FDA Approval Report is delivered in two complimentary formats:
- FirstImpact Survey Analysis Report: a concise written report that reviews the reaction of physicians to the FDA approval of Aubagio, within the MS market. The report also assesses the commercial outcome of this approval by comparing and contrasting FirstImpact poll results with the opinions of investment analysts who have closely monitored the drug’s development.
- FirstImpact Survey Data File: A graphical Excel spreadsheet analysis of the poll results, providing insight into the potential impact of Aubagio’s approval on neurologists’ prescribing decisions.
FirstImpact survey findings show 82 percent of neurologists are generally aware of Aubagio and the majority of these respondents intend to prescribe the drug in the future.
Interviewed physicians did not consider Aubagio’s price to be a major factor influencing its prescribing, compared with its clinical factors.
Interviewed neurologists position the Aubagio as second to Gilenya, while industry analysts see the therapy generating less revenue than BG-12 and Gilenya.
According to poll results, 22 percent of respondents anticipated they will use Aubagio as a monotherapy 90 to 100 percent of the time.
REPORT OVERVIEW
INTRODUCTION
METHODOLOGY
KEY SURVEY FINDINGS
SURVEY RESPONSE ANALYSIS
INTRODUCTION
METHODOLOGY
KEY SURVEY FINDINGS
SURVEY RESPONSE ANALYSIS
- Do you intend to prescribe Aubagio?
- What will be the most important factor in prescribing Aubagio?
- What percentage of total Aubagio prescriptions do you expect to prescribe as a monotherapy?
- In what patient population are you most likely to prescribe Aubagio?
- Which oral therapy (based on available clinical data) do you expect to prescribe most frequently in two years time?
